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…E quelli che s’inarnorono di pratica senza 
scientia  sono  come  il  nocchiere  che  entra 
navilio senza timone e bussola, e che mai ha 
certezza dove si vada…
[He who loves practice without theory 
is like the sailor who boards ship without a 
rudder and compass and never knows where 
he may be cast.] (Leonardo Da Vinci)
Thyroid endocrinology aims to advance 
our knowledge of the physiopathology of 
the thyroid gland. The thyroidologist, like 
all physicians concerned with internal med-
icine, lives in an environment of increasing 
specialization and multiplying subspecial-
ties. This applies also to thyroid research, in 
which the divide between “basic” and “clini-
cal” scientists is often wider than it should 
be. Consequently, the grand challenge that 
Frontiers  in  Thyroid  Endocrinology  faces 
is to provide a common platform for the 
opinions  and  rigorous  investigations  of 
both of them. Of course, the link will be 
the  so-called  “translational  research,”  in 
which both sides of the coin merge in the 
ultimate interest of the patient affected by 
thyroid disease.
I will quote only a few examples of a non-
exhaustive list of ideas and a few examples 
of “hot topics” that are jostling for attention. 
I am fully aware of the limits of this list, but 
my aim is to give a flavor of what and where 
the grand challenges are and what awaits us 
in the near future.
CliniCal issues
Thyroid  disease  and  specific  ages:  preva-
lence,  clinical  manifestations  and  treat-
ment  of  thyroid  disorders  differ  greatly 
during the course of life. In puberty, early 
diagnosis and prevention of thyroid dis-
ease are of tremendous socio-economical 
relevance because a significant fraction of 
goiters develops at this age. The big excep-
tion is iodine deficiency, which represents 
the most common thyroid disease for all 
ages. In adults, iodine deficiency remains a 
worldwide risk that is responsible for mor-
bidity associated with nodular goiter and 
thyroid autonomy. Iodine supplementation 
has been one of the great achievements of 
preventive medicine although it presents 
new  challenges  to  us  as  a  society:  does 
iodine supplementation increase the risk of 
developing thyroid diseases, among which 
thyroid autoimmunity? (de Carvalho et al., 
2009; Weetman, 2009). This question must 
be addressed in a scientifically rigorous fash-
ion. During the first decade of the twenty-
first century, the population reaching 65 
years of age has increased exponentially. 
Thyroid diseases in the elderly are often 
unrecognized and may result in substantial 
morbidity and mortality. There are a vari-
ety of diagnostic and therapeutic problems 
in aged individuals that are relevant not 
only for the endocrinologist, but also for 
the geriatrician and oncologist. The issue 
of subclinical thyroid diseases, its diagnosis 
and whether and how it should be treated 
are still open questions notwithstanding 
years of robust clinical studies. Finally, the 
thyroid nodule is still the center of inter-
est for thousands of investigators and clini-
cians. Thyroid cancer is the most common 
form of malignant endocrine tumor. The 
prognosis of thyroid cancer as a whole is 
generally favorable representing only 0.5% 
of all cancer deaths. However, the prognosis 
for patients with metastatic, iodine non-
avid,  differentiated  thyroid  cancer,  and 
anaplastic cancer remains poor (Boelaert, 
2010). What controls the growth of thyroid 
epithelial cells and how this is related to 
genetic or environmental cues are ques-
tions that remain unanswered. Predictors 
of  malignancy  (molecules  expressed, 
hormone levels, or genetic alterations or 
polymorphisms) that could bring about an 
early diagnosis and favorable prognosis of 
thyroid nodules remain a mirage. Future 
research in this field should learn to exploit 
the recent discoveries made in the realm of 
the “omics” technology, including molec-
ular genomics, proteomics, and metabo-
lomics.  Thanks  to  their  global  analysis 
and systematic approach, these techniques 
will produce huge amounts of data that 
will be instrumental for the definition and 
  treatment of the thyroid nodule. From a 
clinical point of view, some differentiated 
cancers are clinically “benign” and would 
not  even  require  radioiodine  treatment. 
Some others are much more aggressive and 
require an aggressive approach. How can 
we distinguish among these cancer types in 
order to decide the most appropriate thera-
peutic approach? A better understanding of 
the molecular pathogenesis of thyroid can-
cer coupled with the significant advances 
made in cancer therapy guarantees prom-
ising and exciting therapeutic options in 
years to come.
TranslaTional issues
Metastatic thyroid cancer poorly sensitive 
to  radioiodine  ablation  has  been  associ-
ated with a number of oncogenic genetic 
abnormalities that are unique. A clear need 
for new therapeutic approaches exists given 
the chemo- and radio-insensitivity of the 
majority  of  these  tumors.  The  identifi-
cation  over  the  last  5–10  years  of  many 
hallmarks of thyroid cancers led to clini-
cal trials of new “molecular” therapies for 
all  histotypes  of  thyroid  cancer,  and  in 
particular  medullary  thyroid  carcinoma. 
A number of kinase inhibitor drugs have 
been shown to exert experimental activity 
and are currently undergoing clinical tri-
als. These agents are mostly multi-kinase 
inhibitors that act mainly on RET, cMET, 
and VEGF, but are also able to affect other 
kinases involved in angiogenesis. There are 
multiple  agents  that  have  been  tested  at 
phase II levels with tremendous results that 
warrant validation in phase III clinical tri-
als. Future trials should perhaps investigate 
the efficacy of combination targeted therapy 
in the first-line treatment of advanced thy-
roid cancer as well as better define their side 
effects, and more importantly, how to treat 
them (Schlumberger and Sherman, 2009; 
Sherman, 2010). Of course, these patients 
are fortunately rare, and research groups 
from different continents will have to join 
forces to gather together large cohorts of 
patients in order to conduct prospective Frontiers in Endocrinology  |  Thyroid Endocrinology    December 2010  | Volume 1  | Article 7  |  2
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the   intriguing possibility of modifying and 
fine tuning at will thyroid hormone action 
in selected tissues. Relevant to this con-
cept was the identification of selective and 
receptor-specific thyroid hormone analogs 
as well as a novel class of biogenic amines 
related to thyroid hormone called “thyron-
amines.”  These  are  putative  metabolites 
of thyroid hormone that have biological 
activities distinct from those of thyroxine 
or T3, and could either play a role in the 
modulation  of  thyroid  hormone  action 
or act as endogenous regulators of other 
distinct pathways (Piehl et al., 2010). All 
this opens the exciting possibility of delib-
erately modifying TH action in a selected 
tissue to achieve therapeutic goals not nec-
essarily related to thyroid itself.
We at Frontiers in Thyroid Endocrinology 
are  pleased  to  take-up  the  challenge  of 
becoming a platform for the publication 
of  high  quality  investigations  concern-
ing all aspects of thyroid research, across 
all species and in all its multiple aspects, 
from molecular biology to clinical studies. 
We welcome contributions including cut-
ting edge discoveries in the areas of thyroid 
physiopathology, basic related science, cel-
lular and animal physiology, as well as, and 
most importantly, therapy and treatment of 
thyroid disorders in humans as far as they 
are  sustained  by  results  of  rigorous  and 
creative investigations. Timely and original 
reviews especially dealing with translational 
aspects will be also favorably considered.
studies. This new avenue of cancer treatment 
represents, in my opinion, the most exciting 
promise of translational thyroidology.
BasiC issues
Finally, the basic science. The last 20 years 
of  basic  thyroid  research  generated  piv-
otal discoveries that opened new frontiers 
in thyroidology. The cloning of the three 
iodothyronine selenodeiodinases and the 
identification of specific thyroid hormone 
transporters  were  breakthroughs  that 
impacted not only on the physiology of 
thyroid hormone action but also on the 
identification of new diseases associated 
with their genetic abnormalities (Bianco 
et al., 2002; Gereben et al., 2008; Visser 
et al., 2008). The regulation of T3 genera-
tion at tissue level has been increasingly rec-
ognized as an important mechanism for the 
control thyroid hormone action. The frac-
tion of T3 that is produced locally from T4, 
and the contribution of locally produced 
T3 to the amount of T3 bound to its recep-
tors varies substantially from species to spe-
cies and from tissue to tissue. In humans, 
approximately 80% of extrathyroidal T3 
derived from T4 is produced intracellu-
larly. This locally produced T3 is a crucial 
factor in several fundamental mechanisms, 
including circulating thyroid homeostasis, 
energy balance, and glucose metabolism. 
The concept that circulating thyroid hor-
mone does not necessarily reflect the tissue 
or cellular thyroid hormone action opens 